CTLA-4 is a critical negative regulator of the immune system and a major target for immunotherapy. However, precisely how it functions in vivo to maintain immune homeostasis is not clear. As a highly endocytic molecule, CTLA-4 can capture costimulatory ligands from opposing cells by a process of transendocytosis (TE). By restricting costimulatory ligand expression in this manner, CTLA-4 controls the CD28-dependent activation of T cells. Regulatory T cells (T regs ) constitutively express CTLA-4 at high levels and, in its absence, show defects in TE and suppressive function. Activated conventional T cells (T conv ) are also capable of CTLA-4-dependent TE; however, the relative use of this mechanism by T regs and T conv in vivo remains unclear. Here, we set out to characterize both the perpetrators and cellular targets of CTLA-4 TE in vivo. We found that T regs showed constitutive cell surface recruitment of CTLA-4 ex vivo and performed TE rapidly after TCR stimulation. T regs outperformed activated T conv at TE in vivo, and expression of ICOS marked T regs with this capability. Using TCR transgenic T regs that recognize a protein expressed in the pancreas, we showed that the presentation of tissue-derived self-antigen could trigger T regs to capture costimulatory ligands in vivo. Last, we identified migratory dendritic cells (DCs) as the major target for T reg -based CTLA-4-dependent regulation in the steady state. These data support a model in which CTLA-4 expressed on T regs dynamically regulates the phenotype of DCs trafficking to lymph nodes from peripheral tissues in an antigen-dependent manner.
INTRODUCTION
Cytotoxic T lymphocyte associated protein 4 (CTLA-4) is essential to prevent aberrant T cell responses against self-proteins. Mice genetically deficient in CTLA-4 develop a lymphoproliferative syndrome (1, 2) with T cell reactivity to tissue-specific self-antigens, such as PDIA2 (protein disulfide isomerase-associated 2), an enzyme expressed in pancreatic acinar cells (3) . Individuals harboring CTLA-4 mutations exhibit multiple autoimmune features (4, 5) , reflecting the importance of this pathway in controlling T cell responses to self-proteins in humans. Thus, data from mice and humans suggest that CTLA-4-dependent regulation can be elicited by self-antigens and is essential to temper self-reactivity. Nevertheless, the ability of self-antigens to mobilize CTLA-4 expression and initiate CTLA-4-dependent functions has not been directly tested.
Considerable CTLA-4 functional activity is known to map to the forkhead box P3 (Foxp3) + regulatory T cell (T reg ) population, and ablating CTLA-4 in this compartment results in lethal immune dysregulation (6) . It has been proposed that the CTLA-4 pathway represents a core mechanism of T reg suppression (7) that is indispensable for normal immune homeostasis. Accordingly, the loss of CTLA-4 impairs T reg function in multiple models (3, 6, (8) (9) (10) (11) (12) (13) (14) , and conversely, CTLA-4 overexpression can confer suppressive capacity (15, 16) . Recently, single-cell RNA sequencing analysis confirmed Ctla4 as a component of the core gene signature shared by all T regs , independent of additional phenotypic variation (17) such as that associated with tissue residency at particular anatomical sites (18) . The capacity to use the CTLA-4 pathway therefore appears to be hardwired into the T reg lineage.
T reg -expressed CTLA-4 functions in a cell-extrinsic manner to control the CD28-dependent activation of naïve T cells by restricting their access to costimulatory ligands. This function can be mediated by ligand competition, given the higher affinity of CTLA-4 for the ligands (CD80 and CD86) it shares with CD28 (19) . CTLA-4 is also able to capture its ligands from antigen-presenting cells (APCs) by transendocytosis (TE), targeting them for degradation within the recipient cell (20) . Multiscale spatiotemporal modeling of T cell-APC interactions suggests that simple ligand competition by CTLA-4 is not sufficient to interrupt CD28 engagement, with TE being required to effectively eliminate the costimulatory signal (21) . Additional mathematical modeling indicates that ligands need to be of optimal affinity to maximize TE and that the process is a quantitative one, dictated by the expression levels of ligands and receptors (22, 23) . T regs from humans with heterozygous CTLA-4 deficiency show a quantitative defect in TE and suppressive function (5) , whereas in model systems where APCs have been subjected to TE, ligand loss is proportional to the number of CTLA-4-expressing cells and the amount of remaining ligand directly correlates with the number of T cells that can be induced to proliferate (23) . Thus, establishing the identity of the cellular partners involved in CTLA-4 regulation in vivo, their expression of ligands and receptors, and their response to stimulation remain important issues in understanding CTLA-4 biology.
Therefore, in this study, we set out to analyze the kinetics of CTLA-4 trafficking in T regs and activated conventional T cells (T conv ) and compare the capacity of these cell subsets to perform CTLA-4-dependent TE in vitro and in vivo. T regs showed constitutive recruitment of CTLA-4 to the cell membrane and performed TE rapidly after T cell receptor (TCR) stimulation. Conversely, T conv relied upon de novo synthesis of CTLA-4 to establish a similar functional capability. We found that although both T regs and activated T conv were inherently capable of CTLA-4-dependent TE, in a competitive scenario in vivo TE was restricted to T regs and was a property of the T reg fraction characterized by high inducible T cell costimulator (ICOS) expression. Further, by combining the expression of green fluorescent protein (GFP)-tagged ligands in vivo with a TCR transgenic approach, we showed that tissue-expressed self-antigens were sufficient to elicit CTLA-4-dependent TE. Last, using gene deficiency, antibody (Ab) blockade, and adoptive transfer approaches, we identified lymph node (LN) migratory dendritic cells (DCs) as the major target of CTLA-4-dependent ligand downregulation in vivo.
RESULTS

Constitutive cycling of CTLA-4 in T regs
According to the TE model, the biologically relevant fraction of CTLA-4 is the cycling pool of CTLA-4 molecules that traffic to the plasma membrane and are available for ligand binding within a given time frame. However, the dynamics of CTLA-4 cycling in murine T regs and T conv , including its modulation by TCR engagement and its relation to the surface and total CTLA-4 pools, has not been ascertained. We therefore quantified cycling CTLA-4 in CD4 T cells by assessing the uptake of labeled anti-CTLA-4 Ab at 37°C for 2 hours. Unlike T conv , a sizeable fraction of T regs exhibited constitutive CTLA-4 cycling ex vivo in the absence of stimulation, despite very limited cell surface expression (Fig. 1,  A and B) . Simple cell surface stains for CTLA-4 therefore greatly underestimate the quantity of functionally relevant membrane-exposed protein. Activation of T regs with anti-CD3/CD28 beads for 6 hours significantly increased cycling CTLA-4 mean fluorescence intensity (MFI) (Fig. 1, A and B) , despite a transient but reproducible decrease in the total CTLA-4 pool (Fig. 1B) . T conv needed prolonged TCR stimulation for CTLA-4 to be induced, consistent with a requirement for de novo production, and the cycling and surface levels were lower than those for T regs at all time points examined in line with the lower total expression of CTLA-4 ( Fig. 1  and fig. S1 ). TE was assessed using Chinese hamster ovary (CHO) cells expressing GFP-tagged CD80 as a source of ligand (20) and measuring ligand capture by flow cytometry. Consistent with the CTLA-4 cycling data, only T regs were capable of TE at 6 hours, whereas both T regs and T conv exhibited TE after 24 hours of stimulation (Fig. 2, A  and B) . Thus, T conv acquired a similar capacity as T regs to elicit TE in vitro once they had been stimulated to up-regulate comparable levels of CTLA-4. Internalization of captured ligands was confirmed by confocal microscopy (Fig. 2, C and D) and further corroborated by the accumulation of captured ligand in the presence of the lysosomal inhibitor bafilomycin A1 (BafA; fig. S2 ).
TE is CTLA-4-dependent and sensitive to low levels of TCR engagement
To distinguish any nonspecific ligand transfer from that driven by CTLA-4, we used T regs isolated from mixed bone marrow (BM) chimeric mice harboring both wild-type and CTLA-4-deficient cells. These animals lack the T cell hyperactivation phenotype seen in germline CTLA-4-deficient mice and therefore allow CTLA-4-deficient cells to be studied in a comparable activation state to wild-type cells. CTLA-4-sufficient T regs efficiently captured CD80-GFP from CHO cells, whereas CTLA-4-deficient T regs present in the same well, distinguished by congenic markers, failed to capture ligand (Fig. 3, A and B). Addition of BafA further increased the GFP signal in CTLA-4-sufficient T regs (Fig. 3, A and B) . The flow cytometry data were corroborated by confocal microscopy, confirming ligand internalization by CTLA-4-sufficient T regs ( fig. S3 ). TE could be elicited at low levels of TCR engagement, with marked ligand uptake at anti-CD3 Ab concentrations of about 30 ng/ml (Fig. 3C and  fig. S4 ). A low level of ligand capture was evident even in the absence of anti-CD3 Ab. Subdividing T regs into effector and resting populations, based on CD45RB and CD62L expression ( fig. S5 ), revealed that this was entirely attributable to the effector T reg subset ( Fig. 3C and fig. S4 ), consistent with their higher expression and cycling of CTLA-4 ( fig. S5 ). Using BMderived DCs, we were able to demonstrate peptide dose-dependent ligand downregulation by TCR transgenic T regs in vitro, and this was inhibited by anti-CTLA-4 Ab ( fig. S6 ).
Preferential TE by T regs in vivo
We previously showed that T regs are able to capture GFP-tagged CD86 in vivo (20) . In these experiments, GFP-tagged ligands were introduced into Rag2 −/− BM cells that could give rise to APC after adoptive transfer to Rag2 −/− hosts. Here, we extended our analysis to CD80 and compared the ability of T regs and T conv to acquire ligands in vivo. CD4 T cells from DO11 × RIP-mOVA mice, which contain a mixture of ovalbumin (OVA)-specific T conv and T regs (24) , were adoptively transferred into mice injected with CD80-GFP-transduced Rag2 −/− BM cells 3 weeks earlier. Antigen was provided by OVA/alum immunization. Although OVA-specific T conv up-regulated CTLA-4 expression in response to immunization (Fig. 4A) , there was little evidence of TE. In contrast, the T reg population robustly captured GFP-tagged CD80 (Fig. 4A) , and its intracellular localization was confirmed by confocal analysis ex vivo ( T regs capture ligands in response to tissue-expressed self-antigen Together with our previous study (20) , the above experiments establish that T regs can capture both CD80 and CD86 in response to immunized antigen in vivo. However, a key unresolved question is whether TE can be triggered in response to self-antigens. To explore this issue, we first asked whether the expression of CTLA-4 by T regs was enhanced at sites of self-antigen recognition. We took advantage of the DO11 × RIP-mOVA mice, in which a T cell response is targeted against the OVA-expressing  cells in the pancreas, ultimately leading to diabetes induction (25) . OVA-specific T regs in the pancreas expressed markedly higher levels of CTLA-4 than those at distant sites ( Fig. 5A ). In contrast, although CTLA-4 was up-regulated in T conv responding to pancreatic antigen, both the proportion of positive cells and the MFI of CTLA-4 staining were much lower than those observed in T regs ( Fig. 5A and fig. S8A ). We noted a tight correlation between CTLA-4 and ICOS expression in T regs across all tissues examined (Fig. 5 , B and C, and fig. S8B ), suggesting that ICOS marks T regs with the highest potential to elicit CTLA-4-mediated TE.
We have previously shown that OVAspecific T regs use CTLA-4 to prevent OVA-specific T conv from causing diabetes in mice expressing the RIP-mOVA transgene (9) . To directly test whether pancreas-expressed antigen was capable of triggering TE, we introduced Rag2 ). This permitted the development of CD80-GFP-bearing APC in a setting where OVA is presented as a tissue self-antigen. Three weeks after reconstitution, mice were injected with CD4 T cells from DO11 × RIP-mOVA mice (containing OVA-specific T regs and T conv ). Antigen-specific T regs isolated from the pancreas of these mice 7 days later showed acquisition of CD80-GFP, and this was most evident in the fraction expressing the highest levels of CTLA-4 ( Polyclonal T regs modulate DC phenotype in a CTLA-4-dependent manner If the presentation of endogenous selfantigens drives TE, then we reasoned that polyclonal T regs should be capable of acquiring ligand in response to self-peptides constitutively presented by APC in the steady state. We therefore adoptively transferred polyclonal CD4 T cells into mice expressing CD80-GFP and looked for evidence of ligand acquisition in splenic T regs in the absence of exogenous stimulation. Seven days after transfer, T regs , but not T conv , had acquired GFP-tagged lig ands in a manner that was blocked by injection of anti-CTLA-4 Ab (Fig. 6, A and B) . Because conventional DCs (cDCs) are recognized as key APC for the maintenance of peripheral tolerance by T regs (26) (27) (28) (29) , we assessed whether CD80-GFP expression within this population was affected by the presence of T cells. In parallel with the increased GFP signal in T regs , we noted a decreased GFP signal in cDCs and a concomitant decrease in Ab staining for CD80 (Fig. 6, C and D) . Levels of CD80 and GFP on macrophages were not altered ( fig. S9A ). These data suggest that polyclonal T regs constitutively perform CTLA-4-dependent TE and modulate the phenotype of cDCs in the steady state. 
Tissue migratory DCs are the primary targets for CTLA-4-based regulation in vivo
Because our data implicated self-antigens as a trigger for TE and cDCs as target cells, we hypothesized that migratory DCs, which transport antigen from tissues, could be an important player in this process. Migratory DCs have been shown to be responsible for the traffic of selfantigens from a range of peripheral tissues including the skin (30), stomach (31) , and endocrine pancreas (30 (Fig. 7, A and B) . We observed that both cDC1 and cDC2 populations within the migratory DC population were affected. Because CTLA-4-deficient mice develop a lymphoproliferative syndrome with widespread immune activation ( fig. S12) , the altered phenotype of migratory DCs might have been influenced by ongoing inflammation since birth. To address this caveat, we performed a short-term (1 day) blockade with anti-CTLA-4 Ab, which elicited the same pattern of changes, with migratory DCs showing increased expression of CD80 and CD86 and resident DCs remaining unchanged (Fig. 7, C and D) . Only at a later time point (day 4) did resident DCs show differences, with increased CD80 in the cDC2 subset. These data are consistent with steady-state CTLA-4-dependent S9C ). To confirm that migratory DCs were targeted by CTLA-4, we used fluorescein isothiocyanate (FITC) skin painting to identify DCs migrating from skin to draining LNs. FITC-labeled DCs that migrated to the LNs were MHCII hi CD11c int and showed increased expression of CD80 and CD86 after CTLA-4 blockade, whereas resident DCs in the same LN remained largely unchanged ( fig. S14) . As a complementary approach, we sought to restore CTLA-4-dependent regulation by reconstituting Rag2-deficient mice with CD4 T cells. This resulted in the down-regulation of CD80 and CD86 on LN migratory DCs, whereas resident DC remained unchanged (Fig. 8 and  fig. S15 ). Again, changes to splenic cDC populations were minimal ( fig. S16 ). If T cells were CD25-depleted before transfer, then the down-regulation of costimulatory ligands was greatly reduced, consistent with T regs being the major elicitors of CTLA-4 function (Fig. 8) . Expanding T regs by injecting interleukin-2 complex (36) reduced cDC ligand expression further ( fig. S17 ). Collectively, these data reveal a notable preference for migratory DCs as the target of CTLA-4-dependent ligand regulation by T regs in vivo.
DISCUSSION
This study builds on our previous work on CTLA-4-dependent TE (20) and reveals that T reg CTLA-4 is constitutively trafficked to the cell membrane, permitting continuous TE by this population in the steady state. Self-antigens are a likely stimulus for this behavior, and we directly demonstrate that T reg encounter with self-antigen expressed in a peripheral tissue can drive high CTLA-4 expression and trigger capture of costimulatory ligands. Although activated T conv are capable of performing TE, we show that in a competitive scenario in vivo, where T regs and T conv specific for the same antigen coexist, TE is almost entirely restricted to the T reg compartment. This holds true for responses to both tissue antigen and immunized antigen and may reflect a failure of T conv in these settings to achieve the very high CTLA-4 levels required for ligand capture. The ability of T regs , but not T conv , to acquire ligand was recapitulated when polyclonal T cells were studied, although, here, distinct TCR repertoires may add an additional variable. The T reg repertoire is believed to be skewed toward recognition of selfproteins (37, 38) , and peripheral T regs express higher levels of Nur-77 than T conv , consistent with ongoing receipt of TCR signals (39, 40) . T regs are thought to continuously respond to self-antigen-derived TCR ligands (24, 41) , which promote their suppressive capacity (42, 43) and guide their anatomical location (24, 41, (44) (45) (46) . Thus, superior TE by T regs may reflect the preferential ability of T regs to interact with and be stimulated by self-antigen-bearing APC, their higher levels of CTLA-4, and longer dwell times. All of these features are consistent with models of how CTLA-4 TE is thought to operate (22, 23, 47) .
Antigen-specific T regs capable of capturing ligands in vivo in our experiments were characterized by high ICOS expression. Furthermore, we identified a tight relationship between ICOS and CTLA-4 expression in T regs , with ICOS positivity being restricted to T regs bearing the highest levels of CTLA-4. Because only the latter were capable of appreciable ligand acquisition, ICOS effectively serves as a marker of T regs with transendocytic potential, perhaps explaining the prognostic value of ICOS + T regs in some cancer settings (48) . The expression of ICOS, along with CD103 and T cell immunoreceptor with Ig and ITIM domains (TIGIT), has been suggested to identify pancreas-infiltrating T regs that have been recently activated by antigens (49) . Because ICOS and CTLA-4 are known to be highly sensitive to CD28 engagement (50, 51) , together, this suggests that the ICOS hi CTLA-4 hi phenotype of T regs with TE potential may reflect a recent history of TCR and CD28 engagement.
Ligand capture by polyclonal T regs in vivo, seen in our experiments, was accompanied by a loss of GFP (and ligand) from cDCs. Because the expression of the GFP-tagged ligand is driven by a ubiquitous viral promoter and costimulatory ligand expression is therefore decoupled from endogenous gene regulation mechanisms, this supports the idea that ligand removal rather than altered gene expression is responsible. Numerous studies have reported CTLA-4-dependent down-regulation of CD80 and CD86 in vitro (6, 20, 52, 53) ; however, relatively few have documented this process in vivo (54) . In the context of graft versus host disease, one study found that T regs were able to decrease costimulatory ligand expression on cDCs in vivo and thereby inhibit fast-phase lymphopenia-induced proliferation (55) . The capacity to down-regulate CD80 and CD86 was linked to the T reg :DC ratio and was lost if T regs were rendered CTLA-4 deficient. These changes are consistent with the TE model and suggest that T reg CTLA-4 acts to continuously dampen costimulatory ligand expression on DCs in the steady state.
T reg -driven down-regulation of CD80 and CD86 on APCs has been documented by numerous groups in a wide variety of experimental systems [reviewed in (56) ]. Therefore, the observation that DCs interacting with T regs in vivo bear a CD86 hi phenotype (57) has constituted a paradox. The notion that the high expression of CD86 reflects the subset of DC (migratory rather than resident) goes some way toward resolving this paradox. The presentation of tissue selfantigens has been shown to map to the migratory DC subset in several systems including in the context of the gastric H + K + adenosine triphosphatase autoantigen (31) and pancreatic islet antigen (30) . Migratory DCs carrying tissue antigen to the draining LNs could conceivably pose the highest risk for triggering a T conv response toward low-affinity self-antigens due to their high expression of MHC class II and costimulatory ligands, even in germ-free-or Toll-like receptor pathway-deficient mice (58) . Such risk might invoke a particular need for T reg -mediated control; it has been reported that migratory DCs entering LNs are actively intercepted by T regs on and around the collagen fibers just under the LN capsule (59) . Furthermore, imaging studies have revealed T regs clustering with both migratory cDC1 in the T cell zone and migratory cDC2 that occupy the interfollicular space by virtue of EBI2-dependent chemotaxis (32, 57) . Consistent with this, our experiments show nondiscriminatory CTLA-4-mediated control of both migratory cDC1 and cDC2.
Using of our study is that it focuses on TE in the steady state and does not address whether the target populations for TE change in the setting of infection. Inflammatory stimuli not only alter DC phenotype but also greatly increase DC migration rates, potentially skewing the DC:T reg ratio. Dynamic changes in cellular phenotypes and ratios may result in different cell types interacting with T reg and undergoing CTLA-4-dependent modification in infectious settings.
Furthermore, inflammation-driven increases in the expression of CD80 and CD86 may elevate them beyond the reach of TE-mediated control.
Collectively, these findings provide new insights into the steadystate operation of one of the most crucial mediators of T reg function. The concept that migratory DCs are continuously modified by T regexpressed CTLA-4 in the steady state may be of particular relevance to the field of checkpoint immunotherapy because migratory cDC1s transport tumor antigens to draining LNs (60, 61) . Understanding the cellular targets of CTLA-4-based regulation will be important for unraveling the synergy between therapeutic targeting of CTLA-4 and programed cell death 1 (PD-1).
MATERIALS AND METHODS
Study design
The goal of this study was to enhance our understanding of the cells that elicit CTLA-4-based immunoregulation in vivo and to identify the APC populations targeted by this process. The experimental approaches include flow cytometry to enumerate population frequencies and/or staining intensity, confocal microscopy to assess captured GFP-tagged ligands, and adoptive transfer studies using genetically modified mice. Sample sizes were based on previous experiments or the limiting factor in a given experiment (e.g., how many donor mice available or cell yields after purification). No outliers were excluded. The number of replicates is provided in each figure legend. There was no randomization and no blinding. Littermate controls were used where appropriate.
Mice BALB/c and DO11.10 mice were from the Jackson Laboratory. Rag2
−/− mice were purchased from Taconic Biosciences. RIP-mOVA mice on a BALB/c background that express a membrane-bound form of OVA under the control of the rat insulin promoter (from line 296-1B) were a gift from W. Heath (Walter and Eliza Hall Institute, Melbourne, Australia). BALB/c CTLA-4 −/− mice were provided by A. Sharpe (Harvard, Boston, MA). DO11.10 and RIP-mOVA mice were crossed (DO11 × RIP-mOVA) as previously described (24) . Mixed BM chimeric mice were made by transferring equal parts of T celldepleted wild type and CTLA-4 −/− congenically marked BM intravenously into irradiated [2 grays (Gy)] Rag2 −/− recipients. Animals were allowed to reconstitute for at least 9 weeks. Mice were housed in individually ventilated cages with environmental enrichment (e.g., cardboard tunnels, paper houses, and chewing blocks) at the University College London (UCL) Biological Services unit. Experiments were performed in accordance with the relevant Home Office project and personal licenses after institutional ethical approval (UCL).
For experimental procedures, 6-to 10-week-old mice (male and female) were used, unless otherwise stated. All injections were carried out in the absence of anesthesia and analgesia, typically between 2 and 11 p.m., and mice were returned to the home cage immediately after the procedure. The first injection for in vivo TE experiments was typically at 10 a.m. The welfare of experimental animals was monitored regularly (typically immediately after procedure and then at least every 2 to 3 days). No adverse events were noted during these experiments. NKp46 (29A1.4), TCR (H57-597), Thy1.1 (OX-7), Thy1.2 (53-2.1), and XCR1 (ZET). Acquisition was performed on LSRFortessa flow cytometer using the FACSDiva acquisition software (all from Becton Dickinson). Analysis of flow cytometry data was performed using FlowJo v10 (FlowJo LLC). MFI denotes geometric mean. The CRAN package Rtsne was used to compute t-distributed stochastic neighbor embedding (t-SNE) in R.
Flow cytometry
In vitro CTLA-4 cycling CD4 cells were isolated from BALB/c LNs using positive magnetic selection (L3T4 MicroBeads, Miltenyi Biotec). Where stated, purified cells were cultured in the presence of anti-CD3 anti-CD28 activation beads (Invitrogen, Thermo Fisher Scientific) at a 2:1 T cell-to-bead ratio for up to 24 hours. Staining was carried out at 4°C to label surface CTLA-4, at 37°C for 2 hours to identify cycling CTLA-4, or after cell fixation/permeabilization to stain the total CTLA-4 pool.
In vitro TE CD80-GFP CHO cells were generated by transduction with pMP71 retroviral vectors carrying a cytomegalovirus (CMV) promoterdriven enhanced GFP-fused mouse CD80. Resulting transfectants were sorted (FACSAria II, Becton Dickinson) for uniform GFP expression. CD4 + T cells from BALB/c LNs or mixed BM chimeric mice were mixed at a 1:1 ratio with CD80-GFP donor CHO cells for up to 24 hours in the presence of soluble anti-CD3 and 100 M TAPI-2 where indicated. Where stated, cells were cultured in the presence of anti-CTLA-4 (4F10. 2BScientific) at 100 g/ml, and 25 nM BafA (Sigma-Aldrich) was used for up to 6 hours before culture termination. For confocal analysis, CD4 + CD25
+ T regs (Regulatory T Cell Isolation Kit, Miltenyi Biotec) were cultured with CD80-GFP donor CHO cells. Live cells were stained and imaged in eight-well Nunc Lab-Tek II Chamber Slides (Sigma-Aldrich) on a C2+ Nikon confocal microscope running NIS-Elements acquisition software. Image analysis was performed in Fiji (ImageJ).
Generation of CD80-GFP mice GFP-tagged CD80 was inserted into a modified pDual lentiviral vector (gift from H. Stauss, UCL, London, UK) and placed under control of a spleen focus-forming virus (SFFV) promoter. Viral particles were produced in human embryonic kidney (HEK) 293 T cell line by cotransfection with pMD.G and pCMV8.91 vectors using FuGENE 6 transfection reagent (Hoffman-La Roche). Harvested supernatant was concentrated by ultracentrifugation, and relative viral titer was estimated on HEK293T cells. Rag2 −/− BM from 4-to 6-week-old donor mice was enriched for Lin -cells using magnetic sorting (Lineage Cell Depletion Kit, Miltenyi Biotec) and transduced at multiplicity of infection of 3.3 in StemSpan serum-free medium (STEMCELL Technologies), supplemented with murine stem cell factor (SCF) (100 ng/ml), thrombopoietin (TPO) (10 ng/ml), and FMS-like tyrosine kinase 3 ligand (Flt3L) (50 ng/ml) (all from PeproTech). After overnight, transduction cells were injected intravenously into irradiated (3.5 Gy) 4-to 6-week-old Rag2 −/− mice.
In vivo TE
For immunization-driven TE, CD4 cells were isolated from DO11 × RIP-mOVA mice and injected intravenously into CD80-GFPexpressing Rag2 −/− recipients. After 24 hours, mice received 100 g of OVA 323-339 /alum intraperitoneally (ip). At day 7, mice were challenged with 100 g of OVA peptide intravenously for 6 hours, in the presence of chloroquine to inhibit lysosomal degradation (600 g ip) for the last 3 hours. Splenocytes were then analyzed. For self-antigendriven TE, CD4 cells were isolated from BALB/c or DO11 × RIP-mOVA mice and adoptively transferred into CD80-GFP-expressing Rag2 −/− recipients expressing RIP-mOVA where indicated. CTLA-4 blockade was performed by intraperitoneal injection of anti-CTLA-4 (4F10) at 500 g per mouse every 2 to 3 days where indicated. Control Ab-treated mice received hamster immunoglobulin G (IgG). After 6 days, mice were injected with 600 g of chloroquine intraperitoneally and harvested at day 7. Cells were isolated from pancreases by liberase/deoxyribonuclease (DNase) digestion and density separation as previously described (25) . Spleens were digested with collagenase/DNase (62) .
Statistical analysis
Statistical analysis was performed using GraphPad Prism version 6, and P values were calculated by two-tailed t test for the means with a 95% confidence interval. Analysis of more than two groups was performed by one-or two-way analysis of variance (ANOVA) if confound by two factors with a 95% confidence interval and corrected for multiple comparisons. Spearman's correlation coefficients with 95% confidence intervals (two-tailed test) were calculated in Fig. 5 ; z scores for comparison of correlation coefficients were calculated using Fisher's r to z transformation.
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